yahoo_financeOriginal article
Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE
Phase 3positiveICOTYDEPositive
AI Analysis
Summary
Johnson & Johnson reported positive Phase 3 results for ICOTYDE, demonstrating sustained skin clearance in patients. The successful trial outcome represents progress toward potential regulatory submission for the dermatological candidate.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
sustained skin clearance demonstrated
Importance:7/10
Sentiment:
0.70
Phase 3dermatologyclinical trialpositive data
Related Companies
Read the original article
Published by yahoo_finance on October 3, 2026 7:06 PM